Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial
Richard Adams, et al.
2021年6月4日～6月8日に完全にバーチャルで開催された、米国臨床腫瘍学会年次集会（2021 Annual Meeting of the American Society of Clinical Oncology®）より、大腸癌や胃癌などの消化器癌の注目演題のレポートをお届けします。臨床研究の第一線で活躍するドクターにより執筆、監修されたレポートを楽しみにしてください。
更新履歴
演題レポート
Colorectal Cancer
Oral Abstract #3504
大腸癌
Oral Abstract #3501＋3502
大腸癌
#3501
The randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13)
Akihito Tsuji, et al.
#3502
Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116)
Sebastian Stintzing, et al.
Oral Abstract #3506
大腸癌
Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial
Andrea Sartore-Bianchi, et al.
Non-Colorectal Cancer
Oral Abstract #4006
胆道癌
Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): Multicenter comparative randomized phase 2b study (NIFTY)
Changhoon Yoo, et al.
Oral Abstract #4007
肝細胞癌
Hepatic arterial infusion chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase 3 trial (The FOHAIC-1 study)
Ming Zhao, et al.
Oral Abstract #4008
肝細胞癌
Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: An interim analysis of a multi-center, phase 3, randomized, controlled clinical trial
Shaohua Li, et al.
Poster Discussion Abstract #4013
食道胃接合部癌
胃癌
Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer: Initial findings of the global phase 3 KEYNOTE-811 study
Janjigian YY, et al.
Poster Discussion Abstract #11524
GIST
Randomized, double-blind, placebo-controlled, phase III trial of pimitespib (TAS-116), an oral HSP90 inhibitor, in patients with advanced GIST (CHAPTER-GIST-301)
Yoshitaka Honma, et al.
Oral Abstract #LBA4001
食道癌
Nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: first results of the CheckMate 648 study
Ian Chau, et al.
Poster Discussion Abstract #4027
食道癌
A phase II study of chemoselection with docetaxel, cisplatin, and 5-fluorouracil as a strategy for organ preservation in patients with resectable esophageal cancer (CROC trial)
Chikatoshi Katada, et al.
Oral Abstract #4000
食道癌
ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC)
Rui-hua Xu, et al.